| Autor: |
Alterman JF; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA., Coles AH; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA., Hall LM; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA., Aronin N; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA., Khvorova A; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA., Didiot MC; RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA.; Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. |
| Abstrakt: |
Primary neurons represent an ideal cellular system for the identification of therapeutic oligonucleotides for the treatment of neurodegenerative diseases. However, due to the sensitive nature of primary cells, the transfection of small interfering RNAs (siRNA) using classical methods is laborious and often shows low efficiency. Recent progress in oligonucleotide chemistry has enabled the development of stabilized and hydrophobically modified small interfering RNAs (hsiRNAs). This new class of oligonucleotide therapeutics shows extremely efficient self-delivery properties and supports potent and durable effects in vitro and in vivo . We have developed a high-throughput in vitro assay to identify and test hsiRNAs in primary neuronal cultures. To simply, rapidly, and accurately quantify the mRNA silencing of hundreds of hsiRNAs, we use the QuantiGene 2.0 quantitative gene expression assay. This high-throughput, 96-well plate-based assay can quantify mRNA levels directly from sample lysate. Here, we describe a method to prepare short-term cultures of mouse primary cortical neurons in a 96-well plate format for high-throughput testing of oligonucleotide therapeutics. This method supports the testing of hsiRNA libraries and the identification of potential therapeutics within just two weeks. We detail methodologies of our high throughput assay workflow from primary neuron preparation to data analysis. This method can help identify oligonucleotide therapeutics for treatment of various neurological diseases. |
